{'fraction_non_alphanumeric': 0.011747430249632892, 'fraction_numerical': 0.0, 'mean_word_length': 5.433962264150943, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New cytostatic agents for the treatment of head and neck cancer.

Chemotherapy plays a definite role in the management of head and neck cancers, especially in combination with radiotherapy in patients with possibly curable disease. As far as new agents are concerned, the combinations of paclitaxel or docetaxel and gemcitabine with cisplatin or carboplatin deserve special attention. These regimens should be compared to the more classical combinations of cisplatin with Sefluorouracil or Ifosfamide in phase III trials. A special emphasis should be placed on the evaluation of these new agents in combination with radiotherapy, since all have strong radiopotentiating properties.